Navigation Links
Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies
Date:4/29/2008

s for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the preclinical data and plans and potential efficacy of R788. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "may," "can," "support," "indicate," "potential," "expects" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, potential problems that may arise in the clinical testing and approval process and Rigel's need for additional capital, as well as other risks detailed from time to time in Rigel's SEC reports, including its Form 10-K for the year ended December 31, 2007. Rigel does not undertake any obligation to update forward-looking statements.

Contact: Raul Rodriguez

Phone: 650.624.1302

Email: rrodriguez@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.

Phone: 650.
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
3. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
4. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
7. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
8. Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimers Disease
9. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
10. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
11. Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... , ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 2Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 3Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 4Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 5Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 6Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 7Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 8Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus 2Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus 3Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus 4Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus 5
(Date:7/9/2014)... NEW YORK (July 8, 2014) Researchers from ... College of Medicine of Yeshiva University will present ... being held July 12 July 17 in Copenhagen, ... triggers that could prompt transition from cognitive normality to ... of the Einstein Aging Study , established in ...
(Date:7/9/2014)... highlights, Brian Williams refreshing old school rap classics, and ... A University of Colorado Cancer Center study published in ... also allows researchers, journals, and health advocates to connect ... and prevention. , "No matter what field you,re in, ... around the world," says Chante Karimkhani, MD candidate in ...
(Date:7/9/2014)... The National Institute of Allergy and Infectious Diseases ... has launched an early-stage clinical trial of CRS3123, ... Clostridium difficile ( C. difficile ) infection. ... agent that inhibits C. difficile growth while sparing ... will enroll up to 30 healthy men and ...
(Date:7/9/2014)... A retrospective study conducted by researchers at Tufts ... among adults with intellectual and developmental disabilities, the likelihood ... receiving dental care increased. The findings, published in the ... may help improve interventions designed to address the oral ... researchers reviewed the dental records of 107 patients at ...
(Date:7/9/2014)... kidney and heart disease have raised concerns about the ... in the first study to look closely at this ... the University of Pennsylvania report that older kidney donors ... cardiovascular health as very healthy older people who did ... increasing organ transplant waitlists, the authors of the study ...
Breaking Medicine News(10 mins):Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
... Group, Inc. (SSI),announced today that Siemens Healthcare has ... through SSI,s ClickON(R), ClickON(R),s LinX,offering, and content partnership., ... Healthcare customers,to take advantage of a wide range ... Status, Secondary Billing, Audit Tracking and Note,Posting for ...
... had to become a "difficult patient" before she could get ... her health. , And once the diagnosis was made, she ... "difficult" before she could get the best treatment for scleroderma, ... is a major element. , Mayer, a research assistant professor ...
... PALM BEACH, Fla., Sept 10 If a ... bag of chips or a quart of ice ... emotional eating, which can,now be helped with The ... ), the first vegan, gluten-free vitamin with human,clinical ...
... is a unique online community for people who support affordable health ... ... Columbus, OH (PRWEB) September 10, 2008 -- While politicians dispense their ... are invited to do the same online. The common place to ...
... launches a unique, national weight and stress management program based upon ... ... (PRWEB) September 10, 2008 -- With high gasoline prices, depressed real ... Americans are skyrocketing. For those that attempt to eat their stress ...
... personalized service educates clients about Medicare; identifies best options and ... ... Belleville, Ill. (Vocus) September 10, 2008 ... the services it offers to individuals with disabilities with the ...
Cached Medicine News:Health News:SSI Announces Agreement with Siemens Healthcare 2Health News:Survival instincts propel 'difficult patient' to insist on quality care 2Health News:Survival instincts propel 'difficult patient' to insist on quality care 3Health News:Stress-Related and Emotional Eating Can Be Curbed With the Vitamin Code(TM) Perfect Weight Formula 2Health News:Stress-Related and Emotional Eating Can Be Curbed With the Vitamin Code(TM) Perfect Weight Formula 3Health News:Social Network For Affordable Health Care Supporters Stimulates A New Level of Interactivity and Dialogue 2Health News:Are You A Stress Eater? Revolutionary Program Reduces Overall Stress and Stress Eating Tendencies 2Health News:Are You A Stress Eater? Revolutionary Program Reduces Overall Stress and Stress Eating Tendencies 3Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 2Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 3Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 4Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 5
... Tests are available in 14 configurations including ... using Microgenics Antibody Technology, the SureStep™ MDMA ... care immunoassay targeted to detect MDMA that ... MDEA but no cross-reactivity to any isomer ...
... Our most popular onsite test! QuickScreen™ ... the urine sample, and your choice of ... QuickScreen™ multi-panels offer total flexibility for your ... into the specimen and the built-in timer ...
... products, SEDIPLAST® is a completely closed ... protect laboratory personnel from the risk ... a uniquely designed erythrocyte sedimentation rate ... and convenience as well as reliable ...
... guaiac as a test for the presence of ... compounds present in guaiac to quinones, resulting in ... is present, the heme portion of the hemoglobin ... the release of oxygen from hydrogen peroxide which ...
Medicine Products: